Drugs that contain Migalastat Hydrochloride

1. List of Galafold drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11304940 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11426396 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11357764 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11376244 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11357765 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000011 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US9987263 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US11241422 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US9480682 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US10383864 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US10406143 AMICUS THERAP US Methods for treatment of fabry disease
May, 2027

(4 years from now)

US11033538 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(5 years from now)

US10925866 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(5 years from now)

US10525045 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(5 years from now)

US9999618 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(5 years from now)

US10813921 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(6 years from now)

US9095584 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(6 years from now)

USRE48608 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(6 years from now)

US8592362 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(6 years from now)

US10076514 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Mar, 2037

(14 years from now)

US11234972 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Mar, 2037

(14 years from now)

US11357763 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US11389437 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11389436 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US11278538 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11278537 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11278536 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11278539 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11278540 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11458128 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10251873 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US10471053 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10857141 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10849890 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10849889 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10857142 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10874657 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10874655 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US10874656 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10792278 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10792279 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10799491 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10806727 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US11357761 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11357762 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11357784 AMICUS THERAP US Use of migalastat for treating Fabry disease in pregnant patients
Feb, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023
Orphan Drug Exclusivity (ODE) Aug 10, 2025

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients; A method of reducing podocyte globotriaosylceramide (gl-3) in a fabry patient by administering migalastat; A method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat

Dosage: CAPSULE;ORAL

How can I launch a generic of GALAFOLD before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic